Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome

Basit Öğe Kaydı
dc.contributor.authorSezgin, Canfeza
dc.contributor.authorKurt, Ender
dc.contributor.authorEvrensel, Turkan
dc.contributor.authorOzdemir, Necmettin
dc.contributor.authorManavoglu, Osman
dc.contributor.authorGoker, Erdem
dc.date.accessioned2019-10-27T19:39:27Z
dc.date.available2019-10-27T19:39:27Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes. Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 Mg/m(2)/d) in patients with anthra-cycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment. Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP. Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.en_US
dc.identifier.doi10.1097/01.smj.0000252968.87824.19en_US
dc.identifier.endpage32en_US
dc.identifier.issn0038-4348
dc.identifier.issue1en_US
dc.identifier.pmid17269522en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org/10.1097/01.smj.0000252968.87824.19
dc.identifier.urihttps://hdl.handle.net/11454/40169
dc.identifier.volume100en_US
dc.identifier.wosWOS:000246777300009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofSouthern Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcapecitabineen_US
dc.subjectmetastatic breast canceren_US
dc.titleEfficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcomeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu